Mesoblast a good prospect ... if you have the ticker

18-02-2014 The AgeComments (0)


Mesoblast recently announced that the US Food and Drug Administration (FDA) has cleared the way for the company and its partner Teva Pharmaceuticals to begin the phase 3 trial of its product for congestive heart failure (CHF) - a chronic condition that ...

Read more on The Age

Your Comments

Login to add a comment

There are no comments yet. Be the first and leave a response!

Back to top